AI-generated analysis. Always verify with the original filing.
Instil Bio reported its fourth quarter and full year 2025 financial results, including a net loss per share of $1.21 for Q4 2025 and $10.70 for the full year, and announced a strategic shift to focus on potential acquisitions and in-licensing opportunities. The company's cash position of $76.3 million as of December 31, 2025 is expected to fund its current operating plan beyond 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated March 27, 2026. 104 The cover page of this report has been for
| Metric | Value | Basis |
|---|---|---|
| In-process research and development expenses | $0.00 | GAAP |
| Research and development expenses | $3.50 | GAAP |
| General and administrative expenses | $6.10 | GAAP |
| Restructuring and impairment charges | $0.00 | GAAP |
| Net loss per share, basic and diluted | $1.21 | GAAP |
| Non-GAAP net loss per share, basic and diluted | $0.97 | Non-GAAP |